<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423358</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0011</org_study_id>
    <secondary_id>K23AR050995</secondary_id>
    <nct_id>NCT00423358</nct_id>
  </id_info>
  <brief_title>Treatment of Hypovitaminosis D in Rheumatoid Arthritis</brief_title>
  <official_title>Treatment of Hypovitaminosis D in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study recruits individuals with rheumatoid arthritis (RA) and low vitamin D
      concentrations. Subjects are dosed with vitamin D or placebo for one year. Primary outcome is
      change in bone turnover markers, additionally, bone mineral density and parameters of RA
      status are evaluated throughout the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is twice as common in people with rheumatoid arthritis (RA), compared to age and
      gender-matched controls [1, 2]. Hypovitaminosis D can contribute to osteoporosis pathogenesis
      by decreasing calcium absorption, leading to a decline in serum ionized calcium, a rise in
      parathyroid hormone levels and upregulation of osteoclast activity, leading to loss of
      calcium from the skeleton. Hypovitaminosis D is also common in patients with rheumatoid
      arthritis [3-5], making it an appealing target to potentially improve health in both RA and
      osteoporosis.

      Vitamin D has theoretic potential to modulate RA disease activity, based on the presence of
      vitamin D receptors in lymphocytes, macrophages, chondrocytes, and synovial cells [6].
      Vitamin D, given as the bioactive metabolite 1,25(OH)2D, ameliorates disease activity in
      murine models of RA [7, 8]. However, few studies have evaluated the effect of vitamin D on RA
      disease activity in humans. Two three month open-label studies reported that vitamin D
      reduced RA disease activity [9] and pain levels [10]. By contrast, an eight-week open-label
      study [11] reported no reduction in swollen joint counts, inflammatory markers or cytokine
      levels after vitamin D therapy. The only double-blind, placebo-controlled trial published
      thus far [12] found no significant effect of vitamin D on RA disease activity, but was
      limited by the lack of hypovitaminosis D as a criterion for study entry. Indeed, at baseline
      subjects' mean 25(OH)D levels indicated vitamin D repletion, potentially explaining the null
      effect of vitamin D on RA disease activity.

      Three studies have evaluated the effect of vitamin D on bone mineral density (BMD) in
      patients with RA [13-15]. Researchers [14] randomized 96 subjects with RA to vitamin D (500
      IU/day) and calcium (1000 mg/day) or placebo for two years; vitamin D and calcium therapy
      modestly increased BMD in the spine and hip. In another study [15], 20 subjects randomized to
      daily calcium and 1 Î±-hydroxyvitamin D for up to 24 months experienced similar declines in
      radius and spine BMD compared to 15 controls [15]. Likewise, vitamin D and calcium did not
      prevent bone loss in a prospective cohort study of patients with RA [13]. However, none of
      the studies required hypovitaminosis D as an entry criterion, vitamin D repletion to 25(OH)D
      levels &gt; 32 ng/ml were not evaluated [13, 14] or achieved [15], and low doses of vitamin D
      were administered, potentially limiting skeletal benefits of this therapy.

      We hypothesized that correction of hypovitaminosis D in subjects with RA would decrease
      parathyroid hormone (PTH), increase BMD, improve functional capacity and down-regulate
      inflammatory cytokine production, thereby diminishing disease activity. Vitamin D is
      inexpensive and widely available. If proven beneficial, vitamin D might become a mainstay of
      therapy for subjects with RA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parathyroid Hormone Level</measure>
    <time_frame>1 Year</time_frame>
    <description>Serum parathyroid hormone level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>1 Year</time_frame>
    <description>one year change in mean total hip BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Survey</measure>
    <time_frame>1 Year</time_frame>
    <description>12 month score for physical function domain of SF36 survey; scale 0 to 100 with 0 indicating worst disability and 100 indicating best physical function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ergocalciferol 50,000 IU Twice monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
    <arm_group_label>vitamin D</arm_group_label>
    <other_name>ergocalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatology

        Exclusion Criteria:

          -  Bisphosphonate therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, Shafer MM. Vitamin D insufficiency: disease or no disease? J Bone Miner Res. 2008 Jul;23(7):1052-60. doi: 10.1359/jbmr.080230.</citation>
    <PMID>18302509</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen KE, Bartels CM, Gangnon RE, Jones AN, Gogineni J. An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol. 2014 Mar;20(2):112-4. doi: 10.1097/RHU.0000000000000072.</citation>
    <PMID>24561419</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>hypovitaminosis D</keyword>
  <keyword>bone turnover</keyword>
  <keyword>ergocalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo tablet
placebo: matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo tablet
placebo: matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="12"/>
                    <measurement group_id="B2" value="53" spread="11"/>
                    <measurement group_id="B3" value="58" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone Level</title>
        <description>Serum parathyroid hormone level</description>
        <time_frame>1 Year</time_frame>
        <population>Subject data were analyzed using the intent to treat approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D, n=11</title>
            <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo, n=11</title>
            <description>matching placebo tablet
placebo: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone Level</title>
          <description>Serum parathyroid hormone level</description>
          <population>Subject data were analyzed using the intent to treat approach.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="11"/>
                    <measurement group_id="O2" value="20" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density</title>
        <description>one year change in mean total hip BMD</description>
        <time_frame>1 Year</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D, n=11</title>
            <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo, n=11</title>
            <description>matching placebo tablet
placebo: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>one year change in mean total hip BMD</description>
          <population>Intent to treat analysis</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="0.140"/>
                    <measurement group_id="O2" value="1.151" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form 36 Survey</title>
        <description>12 month score for physical function domain of SF36 survey; scale 0 to 100 with 0 indicating worst disability and 100 indicating best physical function</description>
        <time_frame>1 Year</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D, n=11</title>
            <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo, n=11</title>
            <description>matching placebo tablet
placebo: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form 36 Survey</title>
          <description>12 month score for physical function domain of SF36 survey; scale 0 to 100 with 0 indicating worst disability and 100 indicating best physical function</description>
          <population>Intent to treat analysis</population>
          <units>units from 0 (worst) to 100 (best)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="34.0" upper_limit="44.4"/>
                    <measurement group_id="O2" value="47.7" lower_limit="42.5" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were queried through specific and open ended questions at each study visit. All AEs after randomization were counted and reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D, n=11</title>
          <description>ergocalciferol 50,000 IU Twice monthly
Vitamin D: Ergocalciferol 50,000 IU loading dose then twice monthly for one year</description>
        </group>
        <group group_id="E2">
          <title>Placebo, n=11</title>
          <description>matching placebo tablet
placebo: matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <description>One participant in the treatment arm reported stomach cramping and constipation that resolved within two weeks of stopping calcium supplements, despite continuation of vitamin D therapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen E Hansen, MD, MS</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-3457</phone>
      <email>keh@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

